Parkman Healthcare Partners LLC increased its position in shares of NewAmsterdam Pharma (NASDAQ:NAMS – Free Report) by 20.8% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 300,750 shares of the company’s stock after buying an additional 51,726 shares during the quarter. Parkman Healthcare […]
Exicure (NASDAQ:XCUR – Get Free Report) and NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, profitability, analyst recommendations, earnings and risk. Insider and Institutional Ownership 42.8% of Exicure shares […]
Presentations include new data from OCEAN, ROSE, and ROSE2 Phase 2 clinical trials, demonstrating obicetrapib’s impact on key lipid and lipoprotein biomarkers
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
NAARDEN, the Netherlands and MIAMI, May 03, 2024 NewAmsterdam Pharma Company N.V. , a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of.